razpipadon

Razpipadon (CVL-871) is a selective, small-molecule partial agonist of the dopamine D1 and D5 receptors. Originally discovered by Pfizer and subsequently licensed to Cerevel Therapeutics (which was acquired by AbbVie in 2024), the compound is specifically designed to modulate the dopaminergic pathways involved in motivation and reward. It is currently being evaluated in Phase 2 clinical trials for the treatment of apathy in patients with mild to moderate dementia, including Alzheimer's disease. By acting as a partial agonist, razpipadon aims to provide sufficient dopaminergic stimulation to improve goal-directed behavior and emotional engagement while minimizing the risk of dyskinesia or other side effects associated with full dopamine agonists.